Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer
作者： Pasi Koivisto , Tapio Visakorpi , Olli-P. Kallioniemi
DOI: 10.1080/00365519609168299
关键词: Immunology 、 Prostate cancer 、 Androgen deprivation therapy 、 Prostate 、 Cancer 、 Androgen 、 Hormonal therapy 、 Cancer cell 、 Cancer research 、 Biology 、 Androgen receptor 、 Clinical biochemistry 、 General Medicine
摘要: Since the development and growth of prostate cancer is highly dependent on androgens, androgen deprivation therapy continues to be treatment choice for patients with advanced cancer. The very effective, but responses are often short-lived. We describe here a novel molecular mechanism that may explain why cells become resistant hormonal therapy. Amplification receptor (AR) gene was found selected during in 23% who experienced local tumor recurrence. leads increased expression AR gene, which enables more effectively utilize residual low levels androgens sustaining cell growth. Discovery amplification as possible resistance should prove useful effective endocrine regimens well diagnostic predictive tests failure.
informahealthcare.com参考文章(17)
Olli-P. Kallioniemi, Tapio Visakorpi, Genetic basis and clonal evolution of human prostate cancer. Advances in Cancer Research. ,vol. 68, pp. 225- 255 ,(1996) , 10.1016/S0065-230X(08)60355-3
J. Trapman, H. M. E. B. Sleddens, J. A. Ruizeveld De Winter, P. J. A. Janssen, A. O. Brinkmann, M. C. T. Verleun-Mooijman, A. B. Santerse, F. H. Schröder, T. H. Van Der Kwast, Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. American Journal of Pathology. ,vol. 144, pp. 735- 746 ,(1994)
E Goker, M Waltham, A Kheradpour, T Trippett, M Mazumdar, Y Elisseyeff, B Schnieders, P Steinherz, C Tan, E Berman, Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood. ,vol. 86, pp. 677- 684 ,(1995) , 10.1182/BLOOD.V86.2.677.BLOODJOURNAL862677
Ritva Karhu, Jorma J. Isola, Olli-P. Kallioniemi, Anne H. Kallioniemi, Eija R. Hyytinen, Teuvo Tammela, Tapio Visakorpi, Ann-Christine Syvänen, Genetic Changes in Primary and Recurrent Prostate Cancer by Comparative Genomic Hybridization Cancer Research. ,vol. 55, pp. 342- 347 ,(1995)
Donald J. Tindall, Jaime E. Perry, Androgens Regulate the Expression of Proliferating Cell Nuclear Antigen Posttranscriptionally in the Human Prostate Cancer Cell Line, LNCaP Cancer Research. ,vol. 56, pp. 1539- 1544 ,(1996)
A Kallioniemi, O. Kallioniemi, D Sudar, D Rutovitz, J. Gray, F Waldman, D Pinkel, Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors Science. ,vol. 258, pp. 818- 821 ,(1992) , 10.1126/SCIENCE.1359641
Miguel Beato, Peter Herrlich, Günther Schütz, Steroid hormone receptors: Many Actors in search of a plot Cell. ,vol. 83, pp. 851- 857 ,(1995) , 10.1016/0092-8674(95)90201-5
O. P. Kallioniemi, A. Kallioniemi, W. Kurisu, A. Thor, L. C. Chen, H. S. Smith, F. M. Waldman, D. Pinkel, J. W. Gray, ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 5321- 5325 ,(1992) , 10.1073/PNAS.89.12.5321
Z Culig, A Hobisch, M V Cronauer, A C Cato, A Hittmair, C Radmayr, J Eberle, G Bartsch, H Klocker, Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology. ,vol. 7, pp. 1541- 1550 ,(1993) , 10.1210/MEND.7.12.8145761
Tapio Visakorpi, Eija Hyytinen, Pasi Koivisto, Minna Tanner, Riitta Keinänen, Christian Palmberg, Aarno Palotie, Teuvo Tammela, Jorma Isola, Olli-P. Kallioniemi, In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics. ,vol. 9, pp. 401- 406 ,(1995) , 10.1038/NG0495-401